NLS

Through a donation, a new foundation has been formed called Familjen Landegrens stiftelse för medicinsk forskning (Landegren Family Foundation for Medical Research). The purpose of this foundation is to support Uppsala University’s medical research and medical innovation.

The US‑based company has debuted in combined seed and Series A financing to advance a portfolio of mid‑stage neurology and neuropsychiatry drugs in‑licensed from Eisai and Hansoh.

Saphnelo (anifrolumab) has been approved in the US for self-administration as a once-weekly autoinjector, the Saphnelo Pen, for the treatment of adult patients with systemic lupus erythematosus (SLE) on top of standard therapy.

For a long time, restoring vision has been like a search for the holy grail for scientists. And for many patients, being diagnosed with a severe retinal disease has meant progressive, irreversible vision loss. However, the past decade has seen some  of the clearest evidence so far that vision loss can be partially restored, not just preserved.

Following Diamyd Medical’s negative results from the March 27 interim analysis of its DIAGNODE-3 study, the Board of Directors has implemented governance changes to strengthen oversight and strategic direction.

Elicera Therapeutics has resolved to carry out a rights issue of shares of approximately SEK 72.8 million with preferential rights for the company’s existing shareholders.